Glycogen Storage Disease Management and Molecular Insights

Glycogen storage diseases (GSDs) comprise a family of inherited metabolic disorders characterised by defects in enzymes or transporters that regulate glycogen synthesis and breakdown. Clinical manifestations range from life-threatening hypoglycaemia and hepatomegaly in type I variants to neutropenia and inflammatory bowel disease in type Ib. Traditional management relies on strict dietary regimens, including frequent carbohydrate-rich meals and uncooked starch supplementation, to maintain euglycaemia and prevent secondary complications such as hepatic adenomas, renal dysfunction and bone demineralisation. Liver transplantation and emerging cell-based therapies offer definitive correction of metabolic derangements but carry procedural and immunological risks. Recent molecular studies have unveiled key pathophysiological mechanisms—from mitochondrial dysfunction in glucose-6-phosphatase deficiency to splicing defects in prevalent variants—and have driven innovative approaches, including splice-switching oligonucleotides and targeted inhibition of renal sugar transporters. Together, these advances promise to transform GSD management by addressing root causes, improving quality of life and reducing long-term sequelae.

Research from Nature Portfolio

Investigations into the cellular organelle dysfunction in type Ia disease have revealed profound impairments in mitochondrial bioenergetics. Model systems exhibit reduced oxidative phosphorylation capacity, altered tricarboxylic acid cycle intermediates, decreased mitochondrial biogenesis and disrupted membrane potential. Structural analyses demonstrate deranged mitochondrial ultrastructure, while activation of intrinsic apoptotic pathways highlights a novel axis of cellular injury. These findings position mitochondrial preservation and enhancement as promising therapeutic targets to mitigate hepatic steatosis and carcinogenic progression.

Glycogen Storage Disease Management and Molecular Insights publication trend

The graph below shows the total number of articles in glycogen storage disease management and molecular insights across all publications each year (not limited to Nature Index journals).

Technical terms

Glycogen storage disease (GSD): A group of inherited disorders caused by enzyme or transporter deficiencies affecting glycogen metabolism.

Hypoglycaemia: A pathological drop in blood glucose concentration leading to neuroglycopenic symptoms.

Splice-switching oligonucleotide: A short synthetic nucleic acid designed to modify pre-mRNA splicing and restore correct protein expression.

Oxidative phosphorylation: A mitochondrial process coupling electron transport to adenosine triphosphate synthesis.

SGLT2 inhibitor: A pharmacological agent that blocks renal reabsorption of glucose (and related polyols) to lower blood sugar levels.

Neutropenia: A deficiency of circulating neutrophils that compromises innate immune defence.

References

1. A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a with G6PC c.648G>T. Journal of Clinical Investigation (2023).
2. Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care. Reviews in Endocrine and Metabolic Disorders (2024).
3. SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia. Cellular and Molecular Life Sciences (2023).
4. Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa). Scientific Reports (2017).
5. Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs. Nutrients (2021).
6. Liver transplantation in glycogen storage disease type I. Orphanet Journal of Rare Diseases (2014).